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Kefir Inhibits Proliferation and Induces Apoptosis of 
Epithelial Colorectal Adenocarcinoma Cells 
 
Stephany E. El-Hayek 
 
ABSTRACT 
 
 
Kefir is a fermented milk product, to which many health benefits have been attributed. These 
include anti-microbial, anti-inflammatory, immunomodulatory, and metabolic benefits. Most 
importantly, many studies have proven that kefir may have anti-cancerous potential. The current 
study aims at examining the effect of this probiotic on colorectal cancer cells, in vitro. Kefir’s 
anti-cancer potential was tested on Caco-2 and HT-29, colorectal adenocarcinoma cell lines, 
through cytotoxicity, proliferation, and apoptotic assays. Kefir’s cytotoxicity was assessed by 
determining the percentage viability of cells, using the Trypan Blue Exclusion method. After 
determining the IC50, the effect of various concentrations of kefir on the proliferation of Caco-2 
and HT-29 cells was determined. Using WST-1 cell proliferation assay, kefir was shown to be 
anti-proliferative to the cells in a dose and time dependent manner. Through flow cytometry, 
kefir was also shown to induce cell cycle arrest at the G1 phase, which was assumed to be an 
apoptotic effect. This was then confirmed by Cell Death Elisa Plus kit, which showed that 
apoptosis increased with increasing kefir concentration. Western Blot analysis demonstrated that  
kefir induces the overexpression of Bax, while repressing Bcl-2.  
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Chapter I 
Literature Review 
 
1.1 Kefir  
1.1.1 Introduction 
Kefir is a well-known fermented milk product, obtained by the fermentation of milk with kefir 
grains. It is highly consumed in many countries, mostly in Eastern Europe, but also in Asia and 
America (Adriana & Socaciu, 2008; Farnworth, 2005). Around the world, kefir is manufactured 
and marketed as a refreshing, slightly alcoholic beverage, under different names (Kephir, 
Kiaphur, Kefer, Kepi and Kippi) (Adriana & Socaciu, 2008; Angulo, Lopez, & Lema, 1993; 
Farnworth, 2005). The making of kefir dates back to earlier centuries, and since then, many 
health benefits have been attributed to it (Farnworth, 2005). In its modern, consumable form, 
kefir is a beverage of viscous nature. In content, it is slightly carbonated, alcoholic, and acidic 
to some extent (Adriana & Socaciu, 2008; Angulo, et al., 1993; Koroleva, 1988; Simova, et al., 
2002). Nowadays, kefir is recognized as a complex probiotic, and is under study for many 
potential in-vivo and in-vitro positive health effects.  
 
1.1.2 The origin of kefir 
The initial discovery of kefir is said to have been accidental, where milk stored in bags made of 
animal skin, underwent natural and spontaneous fermentation (Farnworth, 2005; Guzel-
Seydem, Seydem, Greene, Tas, & 2006). Kefir originated in the Caucasian mountains of the 
former USSR, and since then it has been associated with general well-being and good health 
(Adriana & Socaciu, 2008; Angulo, et al., 1993; Farnworth, 2005). The name is derived from 
the Turkish word “keif”, meaning “good-feeling” (Adriana & Socaciu, 2008; Powell, 2006).  
Kefir grains, which are used to make kefir, and which contain a mixture of various bacteria and 
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yeast species, were considered a sacred gift from the Prophet Mohammad to his people 
(Powell, 2006).  
 
1.2 Kefir grains 
1.2.1. Microbiology of kefir grains 
Kefir grains comprise a mutualistic symbiotic relationship between around 50 types of 
microorganisms, in a matrix of proteins and polysaccharides (Figure 1) (Abraham & De 
Antoni, 1999; Adriana & Socaciu, 2008; Angulo, et al., 1993; H. C. Chen, Wang, & Chen, 2008; 
Garrote, et al., 2004; Simova, et al., 2002). The symbiosis is extensively strong, where some 
studies showed that pure cultures of certain microorganisms in milk show reduced viability 
and/or low biochemical activity (Garrote, et al., 2004).The identification and isolation of the 
various types of bacteria and yeast found in kefir grains have been rendered difficult by the 
strong association between the many microorganisms. Proteomics, biochemical assays, and 
various molecular techniques (such as, PCR-denaturing gradient gel electrophoresis and 16S 
ribosomal DNA sequencing) have aided in unveiling the identity of many of these 
microorganisms (Adriana & Socaciu, 2008; H. C. Chen, et al., 2008; Garrote, et al., 2004; 
Simova, et al., 2002). Bacteria found in kefir grains include lactose-fermenting, acetic acid, 
mesophilic, thermophilic, lactobacilli, lactococci, streptococci, enterococci, leuconostocs, 
among other types of bacteria (Abraham & De Antoni, 1999; Adriana & Socaciu, 2008; 
Angulo, et al., 1993; H. C. Chen, et al., 2008; Garrote, et al., 2004; Simova, et al., 2002). 
Following is a list of most, but not all, bacterial species that constitute kefir grains: Lactobacillus 
kefir, Lactobacillus delbrueckii, Lactobacillus kefiranofaciens, Lactobacillus rhamnosus, Lactobacillus 
kefirgranum, Lactobacillus casei, Lactobacillus parakefir, Lactobacilli paracasei, Lactobacillus brevis,  
Lactobacillus fructivorans, Lactobacillus bulgaricus, Lactobacillus plantarum, Lactobacillus hilgardii, 
Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus viridescens, 
Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Streptococcus thermophilus, Enterococcus 
durans, Leuconostoc sp., Leuconostoc mesenteroides (reported as Leuconostoc kefir  by Ottogalli, Galli, 
Resmini, & Volonterio, 1973), Acetobacter sp., Acetobacter pasteurianus (reported as Acetobacter 
rancens by Ottogalli et al. 1973), Acetobacter aceti, Bacillus sp., Micrococcus sp., Bacillus subtilis, and 
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Escherichia coli  (Abraham & De Antoni, 1999; Adriana & Socaciu, 2008; Angulo, et al., 1993; H. 
C. Chen, et al., 2008; Garrote, et al., 2004; Simova, et al., 2002). Among all these, lactic acid 
bacteria comprise the majority of kefir grains bacterial species (Simova, et al., 2002). Among 
the Lactobacillus species, L. bulgaricus and L. helveticus are the dominant species (Simova, et al., 
2002). 
Kefir yeasts, on the other hand, are less well characterized than their prokaryotic partners in 
symbiosis (Adriana & Socaciu, 2008). They make up around 15% of the microorganisms in 
kefir grains (Simova, et al., 2002). Kefir grains host a diverse community that includes but is 
not limited to: 
Kluyveromyces marxianus, Candida friedrichii (reported as Saccharomyces lactis by Ottogalli et al. 1973) 
and as Kluyveromyces lactis by Angulo et al. 1993), Saccharomyces sp., Candida pseudotropicalis, 
Saccharomyces cerevisiae, Candida tenuis, (reported as Saccharomyces carlbergensis by Ottogalli et al. 
1973), Saccharomyces unisporus, Candida inconspicua, Saccharomyces exiguous, Candida maris (reported as 
Torolopsis holmii by Iwasawa et al. 1982), Saccharomyces turicensis, Candida lambica, Saccharomyces 
delbrueckii, Candida tannotelerans, Saccharomyces dairens, Candida valida, Torulaspora delbrueckii, Candida 
kefyr, Brettanomyces anomalus, Candida holmii, Issatchenkia occidentalis, Yarrowia lypolytica and Pichia 
fermentans (Abraham & De Antoni, 1999; Adriana & Socaciu, 2008; Angulo, et al., 1993; 
Marshall & Wendy, 1985; Simova, et al., 2002). Non-lactose fermenting yeasts make up the 
majority of the fungal species within kefir grains (Simova, et al., 2002). The diverse types of 
yeasts contribute to the symbitotic relationship through producing compounds that act as 
growth stimulants for the bacteria (Adriana & Socaciu, 2008) .   
It is important to note, however, that the microflora of kefir grains from different sources 
exhibit some discrepancies in composition (Abraham & De Antoni, 1999; Angulo, et al., 1993; 
Farnworth, 2005). In addition, during the production of kefir, the microflora of the grains used 
for inoculation is seldom different from the microflora of the final fermented product. This 
further complicates the microbiological study of kefir, and renders comparison of experimental 
results obtained using different kefir grains difficult (Farnworth, 2005; Garrote, Abraham, & 
De Antoni, 2000; Golowczyc, Mobili, Garrote, Abraham, & De Antoni, 2007; Marshall & 
Wendy, 1985).  
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                                       Figure1: Scanning electron micrograph of a kefir grain. 
                                       Source: Adriana & Socaciu, 2008 
 
 
1.2.2 Metabolic activity of the co-cultures 
Among the bacterial and yeast species found within kefir grains, there are some which utilize 
and/or ferment lactose, and those that depend on energy sources other than lactose (Adriana 
& Socaciu, 2008). Lactose-fermenting yeasts degrade lactose directly, converting it into ethanol 
and carbon dioxide. Lactic acid bacteria, which possess the hydrolyzing enzyme β-galctosidase, 
convert the disaccharide into galactose and glucose. The released monomers are the substrates 
on which the non-lactose fermenting yeasts depend for energy. These fungal species convert 
the monosaccharides into ethanol (Adriana & Socaciu, 2008; Farnworth, 2005). Ethanol, along 
with acetyldehyde, diacetyl, acetic acid, and carbon dioxide are all products resulting from yeast 
metabolic reactions (Figure 2) (Adriana & Socaciu, 2008). Each of these compounds 
contributes to the taste, aroma, and texture of kefir (Adriana & Socaciu, 2008; Farnworth, 
2005; Simova, et al., 2002).  
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Figure 2: Simplified model of lactose metabolism in bacteria and yeast cultures of kefir grains. 
Source: Adriana & Socaciu, 2008 
 
 
1.3 Preparation of kefir 
Traditionally obtained by the fermentation of cow milk, nowadays, kefir can commercially be 
made from several types of milk, such as goat or soymilk. Fermentation is achieved by 
inoculating pasteurized milk with kefir grains, which are small, white grains of irregular shape,  
ranging in size between 1 to 3 cm. They are insoluble in water and look like the florets of a 
cauliflower plant (Abraham & De Antoni, 1999; Adriana & Socaciu, 2008; Angulo, et al., 1993; 
Farnworth, 2005; Marshall & Wendy, 1985). During fermentation, which typically takes around 
24 hours at 20-23oC, kefir grains undergo an approximate 25% increase in mass (Angulo, et al., 
1993; Marshall & Wendy, 1985). Kefir grains can be reused for subsequent inoculation; their 
viability is only maintained through their continuous inoculation into fresh milk (Adriana & 
Socaciu, 2008; Farnworth, 2005; Marshall & Wendy, 1985; Simova, et al., 2002). At the 
beginning of the fermentation process, lactic acid streptococci bacteria multiply exponentially. 
This causes a reduction in the pH, which in turn favors the growth of lactobacilli, and inhibits 
the growth of the streptococci. Meanwhile, compounds produced by the yeasts in the mixture, 
allow for the further growth of aroma-producing heterofermentative streptococci. Towards the 
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end of the fermentation process, lactic acid bacterial growth expands as that of acetic acid 
bacteria and yeasts declines, which defines the composition of the fermented milk product 
(Koroleva, 1988; Marshall & Wendy, 1985; Simova, et al., 2002).  
 
1.4. Characteristics of kefir 
The complex and dynamic nature of the microbial population that makes up kefir grains is 
associated with many of kefir’s physical and chemical properties (Abraham & De Antoni, 1999; 
Adriana & Socaciu, 2008; Angulo, et al., 1993; Marshall & Wendy, 1985). The pH, viscosity, 
taste, and chemical constitution of the final fermented product are all a function of the bacteria 
and yeast within the kefir grains that were used to ferment the milk (Table 1). These 
characteristics are also affected by the conditions used for the process of fermentation, which 
may include duration of fermentation, size of initial inoculums used, temperature, and 
agitation, as well as by the type of milk used (Abraham & De Antoni, 1999; Adriana & Socaciu, 
2008; Angulo, et al., 1993; Marshall & Wendy, 1985; Simova, et al., 2002). Kefir is a refreshing, 
slightly alcoholic, carbonated, and acidic drink (Adriana & Socaciu, 2008; Angulo, et al., 1993; 
Koroleva, 1988; Marshall & Wendy, 1985; Simova, et al., 2002). In regards to taste and flavor, 
kefir has a yeasty mouth-feel and a slightly pungent and acidic taste. It is a viscous and creamy 
drink (Adriana & Socaciu, 2008; Koroleva, 1988; Marshall & Wendy, 1985; Simova, et al., 
2002). The alcoholic content of kefir has been shown to vary according to preparation 
methods and other variables, but usually ranges between 0.01-2% (Koroleva, 1988; Powell, 
2006; Simova, et al., 2002). With respect to acidity, the pH of kefir lies between 4.1-4.6 
(Adriana & Socaciu, 2008; Farnworth, 2005; Powell, 2006). Ethanol, which also affects the 
taste, is produced primarily by yeast fermentation, and is what gives kefir its alcoholic nature. 
Carbon dioxide, although tasteless, brings out the tingling feel, characteristic of kefir. Diacetyl 
and acetyldehyde, intermediates in kefir grains metabolism, contribute to the flavor and 
viscosity of the fermented milk product. Acetic acid, another metabolic product, also affects 
taste and flavor (Adriana & Socaciu, 2008; Farnworth, 2005). 
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     Table 1: Characteristics of kefir 
     Source: Simova, et al., 2002 
 
1.5 Chemical composition of kefir 
Regarding chemical composition, several studies have suggested that kefir contains essential 
vitamins; however a consensus about the identity of these vitamins has yet to be reached, and 
the composition may differ according to preparation. Vitamins that may be found in kefir 
include: folic acid, biotin, B12, B1, B2, thiamine, and pyridoxine (Farnworth, 2005; Powell, 
2006; Simova, et al., 2002). Compared to unfermented milk, kefir is a richer source of vitamins  
(Powell, 2006). On the other hand, the amino acid composition of kefir is known to include 
the essential amino acids Leucine, Lysine, and Valine, as well as the non-essential amino acids 
Alanine, Aspartic acid, and Serine. In addition to the previously mentioned acetyldehyde and 
diacetyl, kefir is also characterized by other compounds such as formic, succinic and propionic 
acids, as well as isoamyl alcohol, and acetone, which contribute to its unique taste (Farnworth, 
2005; Powell, 2006). Lactic acid is the predominant type of organic acids in kefir (Farnworth, 
2005; Powell, 2006; Simova, et al., 2002). Kefir also contains enzymes, such as proteinases and 
peptidases, produced by the microorganisms within kefir grains. These enzymes and their 
products, are necessary for proper metabolism and growth of the microorganisms, and are also 
assumed to be bioactive components related to kefir’s beneficial effects (Abraham & De 
Antoni, 1999; Adriana & Socaciu, 2008).   
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1.6 The matrix 
The various bacterial and fungal species, living in symbiosis within kefir grains, are suspended 
in a matrix which consists of proteins and several types of polysaccharides. These components 
are produced and secreted by the microorganisms themselves (Abraham & De Antoni, 1999; 
Angulo, et al., 1993; Farnworth, 2005; Kooiman, 1968; Lee, et al., 2007). About 34% - 47% of 
the dry weight of the kefir is made of proteins and polysaccharides respectively (Abraham & 
De Antoni, 1999). The different polysaccharides, produced by several bacterial species, 
especially lactic-acid bacteria, are cell-surface components. These are often lost to the 
extracellular milieu or secreted, hence they are termed exopolysaccharides (Farnworth, 2005). 
 
1.6.1 Kefiran 
The most studied exopolysaccharide in kefir, kefiran, makes up approximately 24% of the dry 
weight of kefir grains (Kooiman, 1968). Kefiran is a branched, water-soluble polymer that 
contains approximately equal amounts of D-glucose and D-galactose (Figure 3) (Abraham & 
De Antoni, 1999; Angulo, et al., 1993; Kooiman, 1968). Initially through experiments involving 
methylation and periodate-oxidation, the structure of kefiran was determined (Kooiman, 
1968).  
The linkages inside this glucogalactan may explain its relatively high resistance to enzymatic 
degradation (Kooiman, 1968). It is important to note that kefiran is one of several 
exopolysaccharides found in kefir grains, yet it is the most well known since many of kefir’s 
health benefits may be attributed to it (Lee, et al., 2007; Powell, 2006). Kefiran is produced by 
bacteria, mainly lactobacilli, within the kefir grains (Abraham & De Antoni, 1999; Angulo, et 
al., 1993; Kooiman, 1968). Lactobacillus brevis is one of the major producers of kefiran (De 
Vuyst & Degeest, 1999).   
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     Figure 3: Structure of kefiran 
     Source: Kooiman, 1968 
 
 
1.7 Health benefits of kefir 
Due to the health benefits that have been associated with and attributed to kefir consumption, 
it has become known as a complex probiotic.  
 
1.7.1 Probiotics 
A probiotic is defined as a consumable product, containing one or more type of 
microorganisms, which has health benefits. Kefir is distinguished from other probiotics, such 
as yoghurt, by having yeasts as well as bacteria, and by containing a large number of these 
microorganisms (Adriana & Socaciu, 2008; Angulo, et al., 1993; Farnworth, 2005). Most 
probiotics contain lactic acid bacteria, which along with many other bacterial and fungal 
species, are also found in kefir (Farnworth, 2008).  
In general, probiotics are known to ameliorate health in three mechanisms (Oelschlaeger, 
2010). First, probiotic foods may boost immunity, innate and/or acquired, which in turn 
enhances the body’s ability to fight and prevent infectious and inflammatory diseases. The 
effect on the immune system may be through metabolites (ex peptides), cell wall components, 
or DNA (Farnworth, 2005; Hong, Chen, & Chen, 2010; Oelschlaeger, 2010; G. Vinderola, 
Perdigon, Duarte, Farnworth, & Matar, 2006). Second, the microorganisms inside the 
consumed foods may affect other microorganisms, commensal or pathogenic, in the host 
body. Thus, they may aid against infections and in maintaining a stable microflora. One way in 
which probiotics achieve this is by competing with pathogens for limited resources, such as 
iron. Moreover, they may secrete antimicrobial agents, such as bacteriocins, which are 
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produced by several types of Gram-positive and Gram-negative bacteria, and deconjugated bile 
acids, which have stronger antimicrobial agents than the host’s bile salts. Probiotics may also 
possess anti-adhesive and anti-invasive effects against possible pathogens; however the 
mechanisms behind these effects are not completely understood. Third, probiotics may exert 
their effects by targeting microbial products or host products. For instance, probiotics may 
inhibit the production of bacterial and fungal toxins, which are the causative and active agents 
in many diseases and infections (Oelschlaeger, 2010).  
 
1.7.2 Kefir: a complex probiotic 
As one of the most complex consumed probiotics, kefir has been associated with many health 
benefits. Many studies have demonstrated that kefir has immunostimulatory and 
immunomodulatory effects, antimutagenic, as well as antitumorgenic effects (Cevikbas, et al., 
1994; C. Chen, Chan, & Kubow, 2007; H. C. Chen, et al., 2008; de Moreno de Leblanc, Matar, 
Farnworth, & Perdigon, 2007; Guven & Gulmez, 2003; Hong, et al., 2010; Kubo, Odani, 
Nakamura, Tokumaru, & Matsuda, 1992; Lee, et al., 2007; Liu, Chen, & Lin, 2005; Maalouf, 
Baydoun, & Rizk, 2011; Matsuu, et al., 2003; Murofushi, Shiomi, & Aibara, 1983; Nagira, et al., 
2002; Rizk, Maalouf, & Baydoun, 2009; Rodrigues, Carvalho, & Schneedorf, 2005; Shiomi, 
Sasaki, Murofushi, & Aibara, 1982; Thoreux & Schmucker, 2001; G. Vinderola, Perdigon, 
Duarte, Farnworth, et al., 2006). In addition, kefir has been shown to possess antibacterial and 
antifungal against many species (Cevikbas, et al., 1994; Garneau, Martin, & Vederas, 2002; 
Garrote, Abraham, & De Antoni, 2000; Golowczyc, Mobili, Garrote, Abraham, & De Antoni, 
2007; Rodrigues, et al., 2005; Silva, Rodrigues, Filho, & Lima, 2009). On the other hand, 
gastrointestinal, metabolic and nutritional effects have also been attributed to kefir and kefir 
grains (de Vrese, Keller, & Barth, 1992; de Vrese, et al., 2001; Maeda, Zhu, Omura, Suzuki, & 
Kitamura, 2004; St-Onge, et al., 2002; Tamai, Yoshimitsu, Watanabe, Kuwabara, & Nagai, 
1996; Urdaneta, et al., 2007). 
These beneficial effects that kefir and kefir grains have shown may be attributed to bioactive 
ingredients within them. These include the exopolysaccharides, bacterial DNA, cell wall 
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components, as well as peptides (Hong, et al., 2010; Thoreux & Schmucker, 2001; G. 
Vinderola, Perdigon, Duarte, Farnworth, et al., 2006). 
 
1.7.3 Nutritional and gastrointestinal benefits 
Kefir, as discussed above, is a rich source of many organic and inorganic compounds that 
make it of high nutritional value (Farnworth, 2005) . Kefir has positive effects on the 
gastrointestinal tract as well. Various studies have proved that ingestion of kefir ameliorates 
lactose digestion in lactose intolerant people (de Vrese, et al., 1992; de Vrese, et al., 2001). De 
Vrese et al (2001) explains this property of kefir by the action of β-galactosidase enzyme of the 
microorganisms in kefir, the delayed intestinal transit that they induce, and the alteration of the 
intestinal milieu which in turn reduces symptoms of lactose intolerance (de Vrese, et al., 2001) . 
A study by Urdaneta et al (2007) aimed to examine the kefir’s effect on metabolism and 
enzymatic activity. Their results showed that kefir enhances protein digestion and diminishes 
glycemic index (Urdaneta, et al., 2007). Reduction of blood glucose upon kefir administration 
was also noted by Maeda et al (2004).  
With respect to cholesterol level, the action of kefir is still controversial. While several studies 
have shown that kefir leads to a reduction in cholesterol levels (Maeda, Zhu, Omura, Suzuki, & 
Kitamura, 2004; Tamai, et al., 1996), others have contradicted these results by claiming that 
kefir has no effect on total cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride 
levels (St-Onge, et al., 2002). 
 
1.7.4 Antimicrobial effect of kefir  
Kefir’s anti-microbial abilities have been proven by many studies. Garrote et al (2000) showed 
that milk inoculated with kefir grains had inhibitory effects on both Gram-positive and Gram-
negative bacteria (Garrote, et al., 2000). Bacterial species against which kefir has been shown to 
act include Staphylococcus aureus, Bacillus cereus, Salmonella typhi, Shigella sonnei, Listeria monocytogenes, 
Streptococcus pyogenes, and Escherichia coli (Rodrigues, et al., 2005; Silva, et al., 2009). Moreover, 
kefir was shown to have a protective role against Salmonella enteritidis (Golowczyc, et al., 2007).  
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On the other hand, kefir also possesses anti-fungal properties, where several studies have 
demonstrated its inhibitory effects against Candida albicans, Saccharomyces, and other fungal 
species (Cevikbas, et al., 1994; Rodrigues, et al., 2005). 
The mode of action for kefir’s microbial growth inhibition is assumed to be due to products 
released by kefir grains’ metabolic activity (Adriana & Socaciu, 2008). Compounds such as 
organic acids, hydrogen peroxide, acetaldehyde, diacetyl, carbon dioxide or bacteriocins, may 
act as anti-microbial agents (Adriana & Socaciu, 2008; Farnworth, 2005). For instance, 
hydrogen peroxide, produced by lactic acid bacteria, is known to inhibit the growth of 
Pseudominas spp and S. aureus. 
Lactic acid, a major constituent of kefir, has anti-microbial effects against E. coli and B. cereus, 
while carbon dioxide, produced by yeasts and homofermentative bacteria, inhibits obligate 
aerobes by replacing oxygen. On the other hand, acetaldehyde and diacetyl possess inhibiting 
effects on S. aureus, E. coli, S. typhimurium, and some yeasts. Bacteriocins, produced by lactic 
acid bacteria, can kill other microorganisms through cell membrane interactions (Adriana & 
Socaciu, 2008; Farnworth, 2005; Garneau, et al., 2002).  
 
1.7.5 Immunostimulatory effects of kefir  
At the level of the immune system, many studies have shown that kefir may enhance 
immunity, both innate and acquired. Vinderola and colleagues tested the effect of oral 
administration of kefir, in solid fraction (including bacteria) and liquid supernatant fraction, in 
murine animal models. Previous works by these authors showed that kefir induced a dose-
dependent release of IgA+, IL-4+, IL-6+ and IL-10+ cells in the small intestine of mice, in 
addition to enhancing the phagocytosis (C. G. Vinderola, et al., 2005). Both kefir fractions 
induced an upregulation of TNFα and IL-6 on peritoneal macrophages. On the other hand, in 
adherent cells from Peyer’ s patches, IL-1α, IFNγ, TNFα, IL-6 and IL-10, were unregulated 
upon administration of solid kefir fraction by gavage (C. G. Vinderola, et al., 2005). The same 
lab demonstrated that this same immunomodulatory effect is also obtained when only the 
exopolysaccharide produced by Lactobacillus kefiranofaciens was orally administered into BALB/c 
mice (G. Vinderola, Perdigon, Duarte, Thangavel, et al., 2006). A study by Thoreux and 
Schmucker in 2001, in which 6 months and 26 months old rats were fed with kefir and then 
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injected with cholera toxin, aimed to determine the immuomodulatory effect of kefir in young 
and old rats. In the 6 months old rats, anticholera toxin IgA was upregulated as compared to 
their age-matched controls (not fed kefir).  This upregulation, however, was not detected in the 
senescent rats.  Total IgG titer was increased in both age groups compared to controls, while 
there was no significant difference in nonspecific total IgA titer between the controls and the 
kefir-fed rats (Thoreux & Schmucker, 2001).  
Several studies have suggested anti-inflammatory properties of kefir. Rodrigues et al (2005) 
showed that kefir, as well as kefiran by itself, have an anti-inflammatory effect, inhibiting 
mediators of the inflammatory process. Using murine asthma models, Lee et al (2007) 
supported the claim of kefir’s anti-inflammatory role. Intra-gastric admisitration of kefir caused 
a suppression of inflammatory reaction through a reduction in IgE and cytokine levels (Lee, et 
al., 2007). 
An in-vitro anti-allergic effect of kefir was demonstrated by Chen et al (2008) and Hong et al 
(2010). The treatment of splenocytes and macrophages in vitro, with heat inactivated 
Lactobacillus kefiranofaciens and Lactobacillus kefiri induced the release of IFN-γ and IL-12, 
cytokines involved in Th1 response (H. C. Chen, et al., 2008; Hong, et al., 2010). Furthermore, 
Hong et al (2010) tested the anti-allergic effects of kefir in vivo by oral administration of 
bacterial species from kefir grains, namely, Lactobacillus kefiranofaciens and Lactobacillus kefiri into 
mice in which allergy was induced using ovalbumin. The bacteria- fed mice showed a decrease 
in production of IgE upon ovalbumin sensitization. Flow cytometry and microarray analysis 
suggest that this decrease could be due to the upregulation of certain genes such as Cd2, Stat4, 
and Ifnr, which are involved in inflammation and immune response. Hence, Hong et al (2010) 
have suggested one possible mechanism for the anti-allergic effects mediated by kefir bacteria.  
The exact mode of action, by which kefir functions in the immune system, is still not clearly 
discerned (Hong, et al., 2010). However, several studies have attributed kefir’s 
immunomodulatory effects to the bacterial species within it. Some claim that the bacterial 
DNA could be altering the immune response, while others say that cell wall and peptidoglycan 
components could be the potential immunomodulins (Figure 4) (Hong, et al., 2010; Thoreux 
& Schmucker, 2001; G. Vinderola, Perdigon, Duarte, Thangavel, et al., 2006). Moreover, the 
immunomodulatory effects affiliated with kefir are not affected by the viability of the 
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microorganisms within the kefir, but rather, the same effects are obtained with nonviable 
bacteria (Hong, et al., 2010).  
 
   Figure 4: Possible active ingredients for kefir’s beneficial effects. 
   Source: Farnworth, 2008 
 
1.7.6 Kefir’s antimutagenic effect 
Kefir’s antimutagenic role was explored as well. Matssu et al (2003) aimed to study the 
protective role of kefir against radiation-induced intestinal damage and apoptosis. Rats that 
were fed kefir prior to radiation exposure were less susceptible to the induced damage, than 
the control rats, and showed less apoptotic activity. The level of apoptosis was determined first 
by H&E staining, TUNEL assay, and immunohistochemistry for cascape-3 (Matsuu, et al., 
2003). Similarly, Nigara et al (2002) used HMV-1 and SK-MEL cells, human melanoma cell 
lines, and TIG-1 cells, human normal fibroblast cell lines, to verify if kefir has potential as an 
antimutagenic agent. Their results showed that, upon exposure to UV, cells treated with kefir 
were less damaged than untreated cells. The former underwent less morphology change, and 
kefir inhibited the increase in ROS (reactive oxygen species) induced by UV exposure. 
Moreover, in the kefir-treated cells the level of apoptosis detected was suppressed (Nagira, et 
al., 2002).  
 
1.7.7 Kefir’s anticancerous effect  
Kefir and kefir grains also hold antimutagenic and antitumor potential. Shiomi and colleagues 
were the first to test this potential. The effect of a polysaccharide extracted from kefir was 
examined in 1982, on mice with Sarcoma 180 and Ehrlich carcinoma. The administration of 
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the kefir polysaccharide was done orally on a group of mice and intraperitoneally on another. 
In both cases, tumor inhibition was detected (Shiomi, et al., 1982). In a study, Murofushi et al 
(1983) induced delayed-type hypersensitivity (DTH) in mice using picryl chloride. They then 
fed the mice with the same kefir polysaccharide used by Shiomi et al (1982). The oral 
administration of the kefir polysaccharide had induced a decrease in tumor growth (Murofushi, 
Shiomi, & Aibara, 1983). Similar results were obtained by Kubo et al (1992) who investigated 
kefir’s antitumor activity against Ehrlich carcinoma.  In another study, mice bearing sarcoma 
180 tumor cells were fed kefir. Results showed decrease in tumor size as compared to kefir 
unfed mice. In addition, kefir administration had caused apoptotic tumor cell lysis (Liu, Chen, 
& Lin, 2005). In another in vivo study, the authors determined on the effect of kefir on Lewis 
Lung Carcinoma, and B16 melanoma infected mice respectively. Treatment with kefir inhibited 
metastasis progression as well as tumor growth (Furuwaka, Matsuoka, Takahashi, & 
Yamanaka, 2000). Kefir’s antitumor role was further examined by Cevikbas et al (1994). In this 
study, mice with transplanted fusiform cell carcinomas were intraperitoneally injected with 
kefir. This treatment induced an inhibition of tumor necrosis (Cevikbas, et al., 1994).  
Mammary tumours were also experimented on with kefir. De Leblanc et al (2007) used 4T1, 
mammary tumor cells, and injected them into mice to induce breast tumor formation. Mice 
were then fed with kefir. The authors examined the rate of tumor formation on the kefir-fed 
mice compared to control mice, and kefir caused delayed tumor development, in a dose-
dependent manner (de Moreno de Leblanc, et al., 2007). 
On the other hand, an in-vitro study by Chen et al (2007) determined kefir’s anti-tumorigenic 
and anti-proliferative potential on MCF-7 cells, a breast cancer cell line, and normal human 
mammary epithelial cells. Treatment was done in increasing concentrations, and for MCF-7 
cells, inhibition of proliferation was dose-dependent. Kefir was also cytotoxic to the cancerous 
cells at certain doses, where viability decreased by at least 50%. The normal cells however, 
were not affected by the treatment. Cancer cells were also treated with unfermented milk, and 
the authors reported an increase in their proliferation (Chen, Chan, & Kubow, 2007). In 2009, 
Rizk et al (2009) examined the effect of cell-free fraction of kefir on proliferation and 
apoptosis in leukemic cell lines. Cytotoxicity, proliferation, and apoptosis assays were done one 
HuT-102 malignant T- lymphocytes (Rizk, et al., 2009). In another study in 2011, the same 
authors used CEM and Jurkat cells, HTLV-1-negative malignant T-lymphocytes, to assess 
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kefir’s effect furthermore (Maalouf, Baydoun, & Rizk, 2011) . Both studies verified that 
treating these cells with cell-free fraction of kefir caused a decrease in proliferation and an 
increase in the level of apoptosis in a time and dose-dependent manner (Maalouf, et al., 2011; 
Rizk, et al., 2009).  
 
1.8 Colorectal cancer  
1.8.1 Introduction  
Colorectal cancer (CRC) is the cancer of the large intestine. Most cases of CRC occur in the 
colon, while some originate in the rectum, and rarely in the anus. Obesity, sedentary lifestyle, 
smoking, and alcohol consumption are among the established risk factors of this type of 
cancer (Giovannucci, 2002). Other predisposing factors include age, gender, inflammatory 
bowel disease, and a family history of CRC (Aiello, et al., 2011). 
 
1.8.2 Incidence and prevalence of CRC 
CRC ranks as the 4th most prevalent type of cancer in males, and 3rd in females in the world. Its 
incidence however, varies greatly among different countries and regions (Figure 5) (Parkin, 
Bray, Ferlay, & Pisani, 2005). The highest incidence of this disease occurs in North America, 
Oceania, and eastern Europe, and the lowest incidence in Asia, Africa, and South America 
(Center, Jemal, Smith, & Ward, 2009). CRC is associated with high rates of morbidity and 
mortality, and a high economic burden on health care worldwide (Gellad & Provenzale, 2010).  
In some countries, the incidence of CRC is decreasing, yet in many others it is increasing 
(Center, et al., 2009; Gellad & Provenzale, 2010). The incidence of CRC is highest among 
people over 75 years of age (Laszlo, 2010).  
In the United States, CRC is the 3rd most common type of cancer in both men and women. In 
2009, statistics have shown that 75,590 and 71,380 cases of CRC were diagnosed among men 
and women respectively (Jemal, et al., 2009). As for mortality rates, in 2006, 20.5 males and 
14.5 females out of every 100,000 died from CRC. The annual cost of CRC in the US averages 
between 4.5 to 9.6 billion dollars (American Cancer Society, 2010) . However, both mortality 
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rates and incidence of colorectal cancer are decreasing in the US, due to better diagnosis and 
screening, and improved treatment.  
 
 
Figure 5: Trends in colorectal cancer mortality rates for selected countries in males, 1985 through 2005 
Source: Center, et al., 2009 
 
1.8.3 Diagnosis and screening 
Several screening techniques are available for CRC, some of which allow early detection; while 
others are cancer prevention tools (Bretthauer, 2010; Center, et al., 2009; Gellad & Provenzale, 
2010). The most used method of screening is colonoscopy, a form of cancer prevention tool, 
yet it still has to be evaluated in clinical trials (Bretthauer, 2010; Winawer, 2007). Fecal occult 
blood test is an early detection tool, which has the advantage of being cheap and non-invasive 
(Bretthauer, 2010; Center, et al., 2009; Gellad & Provenzale, 2010). However, it often results in 
false positives, and it only decreases CRC mortality by 16% (Bretthauer, 2010). Flexible 
sigmoidoscopy is a cancer prevention tool. The procedure it requires is costly and invasive, yet 
it has been shown to reduce mortality by 30% (Bretthauer, 2010; Center, et al., 2009; Gellad & 
Provenzale, 2010; Winawer, 2007). Other detection methods include stool DNA testing, 
18 
 
double contrast barium enema, computed tomographic colonography, and fecal 
immunochemical tests (Center, et al., 2009; Gellad & Provenzale, 2010). 
 
1.8.4 Polymorphisms related to CRC 
Certain gene polymorphisms and mutations have been identified to be related to the 
development of CRC. The study of these polymorphisms is crucial in the treatment of CRC 
since they affect the choice of drugs to be used. Examples of these mutations include: 
UGT1A1*28, XPD (Lys751Gln), XRCC1 Arg399Gln, MGMT 2535G>T, VEGF C936T, 
Germline Fc-γ RIIa 131H/H, and GSTP1 Ile105Val (Table 2) (Aiello, et al., 2011). 
 
 
 
    Table 2: Genetic alterations associated with current colon cancer therapies.  
    Source: Aiello, et al., 2011 
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1.8.5 Treatment of CRC 
The drugs used in chemotherapy for metastatic CRC are showing improvement in their results, 
especially with the advent of targeted therapeutic agents. Such drugs can be given alone or in 
combination with the standard drugs (Aiello, et al., 2011; El Zouhairi, et al., 2011; Laszlo, 
2010). 5-fluorouracil, the first chemotherapeutic drug to be developed for CRC, is still used 
nowadays, especially in combination with other targeted molecules. Other standard CRC drugs 
include Irinotecan, and Oxaliplatin (Aiello, et al., 2011; Laszlo, 2010). Anti-angiogenic agents 
are drugs that mainly target VEGF or VEGFR; include Bevacizumab and Aflibercept, among 
others (Figure 7) (Aiello, et al., 2011; El Zouhairi, et al., 2011). Vatalanib, Sunitinib,Vandetanib, 
Cediranib, and AMG 706 are direct inhibitors of VEGFR (El Zouhairi, et al., 2011). 
Bevacizumab is an anti-VEGF monoclonal antibody (Aiello, et al., 2011) . On the other hand, 
Cetuximab and Panitumumab are EGFR antagonists (Figure 6). They too are monoclonal 
antibodies (Laszlo, 2010). Novel therapeutic drugs, still under clinical trials, include mTOR 
inhibitors, PKC antagonists, and Src inhibitors, and KSP inhibitors (El Zouhairi, et al., 2011). 
However, the response post treatment for these mentioned drugs, is often variable, and 
dependent on the underlying polymorphism. The percentage of patients who show positive 
effects is also mostly, low (Aiello, et al., 2011; Laszlo, 2010). For instance, anti-EGFR drugs, 
fail in patients with a K-Ras mutation (Laszlo, 2010) On the other hand, many of these drugs 
have considerable side effects, which include gastrointestinal perforation, myocardial 
infarction, and hypertension (El Zouhairi, et al., 2011; Laszlo, 2010). 
 
      Figure 6: Drugs used for targeted therapy for CRC. 
      Source: El Zouhairi, et al., 2010 
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Figure 7: Targeted therapy for CRC. 
 Source: El Zouhairi, et al., 2010 
 
 
1.8.6 CRC and diet 
Diet is known to affect the occurrence and progression of many types of cancer in general, and 
CRC in particular (Pala, et al., 2011; Sung & Bae, 2010; Vrieling & Kampman, 2010). Certain 
dietary factors are claimed to be associated with the incidence recurrence, and survival of CRC. 
Increased body fat, high consumption of red meat, processed foods, and alcohol lead to higher 
risk of CRC (Vrieling & Kampman, 2010). On the other hand, consumption of certain foods, 
such as yoghurt, fruits, vegetables, cheese, and fish tend to lower this risk (Pala, et al., 2011; 
Vrieling & Kampman, 2010). However, in-vivo studies and trials about the correlation of CRC 
and such nutritional components are few. Firm data about dietary factors’ role in CRC is yet to 
be established (Sung & Bae, 2010; Vrieling & Kampman, 2010).  
 
There have been several in-vitro studies concerning dietary components and their anti-
cancerous potential. These studies have shown that dietary compounds can act as anti-
proliferative and pro-apoptotic agents on colorectal cancer cell lines in vitro. Such agents and 
compounds include osteopontin, fungal extracts, berry extracts, curcumin, and quercetin (Kim, 
et al., 2010; Lavi, Friesem, Geresh, Hadar, & Schwartz, 2006; Lavi, et al., 2010; Likui, Hong, 
Shuwen, Yuangang, & Yan, 2011; McDougall, Ross, Ikeji, & Stewart, 2008; Shehzad, Wahid, & 
Lee, 2010). These aimed to find if the compound or extract of interest could, someday, 
become a therapeutic target for CRC. One such compound, curcumin (diferuloylmethane), has 
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entered several clinical trials, and has completed phase I in some trials for its potential 
employment in CRC treatment. Various studies showed that curcumin was responsible for the 
overexpression of Bax and p53, and the under-expression of Bcl-2 (Shehzad, et al., 2010; Su, et 
al., 2006). 
 
1.9 Apoptotic Pathway 
Bcl-2 acts as a repressor of the apoptotic pathway, while Bax, counters this action, and thus 
promotes apoptosis. The ratio of Bax and Bcl-2 in a cell reflects the activation of the survival 
or apoptotic pathways (Oltvai, Milliman, & Korsmeyer, 1993). The apoptotic pathway, which 
involves the couple Bax and Bcl-2, begins with the activation of AMPK. The latter is known to 
control apoptosis in several cancers, including colorectal cancer (Oda, et al., 2000). 
Downstream of AMPK is p53, whose up-regulation in turn causes the up-regulation of the 
pro-apoptotic Bax and the downregulation of the anti-apoptotic Bcl-2 (Oda, et al., 2000; Prives 
& Hall, 1999). The disturbance in the normal balance between Bax and Bcl-2, in favor of Bax, 
triggers the activation of Caspase-3. This in turn causes the proteolytic cleavage of PARP, thus 
triggering apoptosis (Green & Amarante-Mendes, 1998). 
 
1.10 Purpose of the study 
After the established role of kefir as an anticancerous probiotic, the current study aims to 
investigate the effect of kefir-fermented milk on human colorectal adenocarcinoma cells in 
vitro in comparison to nonfermented milk. 
Specifically, the present study revolved around three main objectives: 
1. Determine the effect of kefir on cytotoxicity of Caco-2 and HT-29 cells. 
2.  Determine the effect of noncytotoxic kefir concentrations on apoptosis, proliferation, 
and cell cycle progression 
3.  Determine the mechanism by which kefir employs its anticancerous effect by studying 
expression of proapototic and anti-apoptotic proteins.  
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Chapter II 
MATERIALS AND METHODS 
 
2.1 Cell lines and culture 
Two human colorectal adenocarcinoma cell lines, Caco-2 and HT-29, were cultured in DMEM 
medium supplemented with 10% FBS and 100U penicillin/streptomycin at 37°C and 5% CO2 
in a humidified chamber. 
 
2.2 Preparation of kefir cell-free Fraction and milk 
Sterilized, pasteurized skimmed milk (150 ml) was inoculated with kefir grains (50 g). 
Inoculated milk samples were incubated at 20°C for 24 hours in a sealed glass container. At the 
end of fermentation, the milk was strained to remove the kefir grains. The yeast and bacteria in 
the filtrate were removed by centrifugation (35,000 rpm for 10 minutes at 4°C). The 
supernatant was stored at -20°C until needed for treatment of cells. On the day of treatment, 
the kefir was thawed and then passed through a 0.45-μm filter and a 0.22-μm filter (Millipore, 
Billerica, MA). This cell free fraction of fermented milk, also termed kefir, was applied directly 
to the cells in different volumes to establish the different concentrations required. 
Sterilized, pasteurized skimmed UHT milk was centrifuged (35,000 rpm for 10 minutes at 
4°C). The supernatant was stored at -20°C until needed for treatment of cells. On the day of 
treatment, the milk was thawed and then passed through a 0.45-μm filter and a 0.22-μm filter 
(Millipore, Billerica, MA) successively. The filtrate was applied directly to the cells in different 
volumes to establish the different concentrations required. 
 
2.3 Antibodies and reagents 
Mouse monoclonal IgG anti-β-Actin, anti-Bax, and anti-Bcl2 antibodies were obtained from 
Santa Cruz Biotechnology.  
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Anti-mouse IgG HRP-conjugated secondary antibody was obtained from Promega.  
Propidium Iodide (PI) was obtained from Sigma LifeScience.  
 
2.4 Cytotoxicity: Trypan Blue Exclusion Method 
HT-29 and Caco-2 cells were grown in 24 well plates (growth area: 2cm2) at a density of 2x106 
cells/ml. Cells were allowed to reach 50% confluency for 24 hours after seeding, and then they 
were treated with milk and kefir at the following concentrations (volume/volume): 5%, 10%, 
15%, and 20%. Control wells were left untreated.  After 24, 48, and 72 hours, the supernatant 
from each well was collected, cells were washed with PBS, and the PBS washes were added to 
the supernatant of each well. Cells were then trypsinised and collected separately from the well 
contents and PBS. 20µl from each collection tube was mixed with 20µl of Trypan Blue. 10µl of 
this mixture was placed in a counting chamber under the microscope, and the number of living 
and dead cells was recorded accordingly. For each well, two countings were done separately, 
PBS washes/well supernatant and trypsinised cells.  Under the microscope, dead cells appear 
blue, since they are permeable to Trypan Blue, while viable cells exclude the stain and thus 
appear bright.  The percentage of viable cells was reported. 
 
 
2.5 Proliferation: Cell Proliferation Reagent (WST-1) 
HT-29 and Caco-2 cells were seeded in 96 well plates (growth area: 0.6 cm2) at a concentration 
of 1x106 cells/ml. After 24 hours of seeding, cells were treated with milk and kefir at the 
following concentrations (volume/volume): 5%, 10%, 15%, and 20%. Control wells were left 
untreated.  For every milk and kefir concentration, a blank well was prepared, containing only 
media and the corresponding volume of kefir or milk. After 24, 48, and 72 hours, 10 µl of Cell 
Proliferation Reagent (WST-1; Roche, Germany) was added to each well. The plates were 
incubated at in a humidified incubator (37°C) in 95% air and 5% CO2 for 1.5 hours. WST-1 is 
a tetrazolium salt that on contact with metabolically active cells is cleaved to produce formazan 
dye by mitochondrial dehydrogenases. Quantitation of formazan is done colorimetrically at 
450 nm. The absorbance of the each blank well was subtracted from the corresponding sample 
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well. The results were normalized to the untreated controls, and the percent proliferation was 
reported. 
 
2.6 Cell Cycle Analysis: Flow Cytometry 
Caco-2 and HT-29 cells were seeded in 6 well plates (growth area: 9.5 cm2).When the plates 
reached full confluency, cells were treated with noncytotoxic kefir, and corresponding milk 
concentrations. Treatment was done for 24 hours, with 10 % milk and kefir, in addition to 
nontreated controls.  At the end of the treatment period, cells were trypsinized and detached, 
then centrifuged at 1200 rpm at 5°C for five minutes. The pellet was washed and resuspended 
in 1 ml of ice-cold 1 × phosphate-buffered saline (PBS), and centrifuged again under the same 
conditions. The pellet was resuspended in 1 ml of ice-cold 1 × PBS, and ethanol was added to 
a final concentration of 70%. The fixed cells were left overnight at -20oC. The following day, 
cells were centrifuged and washed with PBS. The pellet was resuspended in 500 μl of 1x 
binding buffer (prepared from the 10X stock), and then 10μl of propidium iodide (PI) was 
added to each sample. The samples were incubated in the dark for 10 minutes.  
Cells were analyzed using an Accuri C6 flow cytometer (Ann Arbor, MI USA), which indicated 
the distribution of the cells into their respective cell-cycle phases based on their DNA content. 
Sub-G0/G1 cells were less than 2n, G0/G1 cells were 2n, S/M phase cells were >2n. Cell 
DNA content was determined by CFlow® Software. An increase in cells in the pre-G phase is 
indicative of an increase in cell death. The percentage of cells in the sub-G0/G1 phase was 
compared to that of the control. 
 
2.7 Apoptosis: Cell Death Elisa Plus Kit 
To confirm the apoptotic effect of kefir on colorectal cancer cells, the Cell Death Elisa Plus kit 
was used. The non-ctytotoxic concentrations of kefir were used to assess the effect of kefir 
and milk on apoptosis. Milk was also used as control. HT-29 and Caco-2 cells were grown in 
96 well plates (growth area: 0.6 cm2) at a concentration of 1x105cells/ml. After 24 hours, cells 
were re-fed and then treated with milk and kefir at the following concentrations 
(volume/volume): 5%, 10%, 15%. Control wells were left untreated.  After 24 and 48 hours of 
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treatment, cells were lysed with 200 μl of the provided lysis buffer, and incubated for 30 
minutes at room temperature. The plates were then centrifuged for 10 minutes at 200g. 20 μl 
of the supernatant were placed in streptavidin-coated microtiter plates, followed by the 
addition of biotin-labeled anti-histone and peroxidase-conjugated anti-DNA antibodies. The 
anti-histone antibody, bound to the plate via biotin-streptavidin, also bound histones from 
released nucleosomes. The plate was then incubated at room temperature for 2 hours, after 
which ABTS (2, 2′-azino-di(3-ethylbenzthiazolin-sulfonate)) was added as a substrate for 
peroxidase enzyme. Enrichment factor was calculated as the recorded absorbance of each 
sample, divided by that of the untreated cells, according to manufactures’ instructions. 
 
2.8 Western Blot Analysis 
 Caco-2 cells were seeded in 6 well plates (growth area 9.5 cm2). When the plates reached full 
confluency, cells were treated with non-cytotoxic kefir, and corresponding milk concentrations. 
Treatment was done for 48 hours with 5% and 10% milk and kefir, in addition to nontreated 
controls.  At the end of the treatment period, cell lysates were prepared by scraping the cells in 
a sample buffer consisted of 4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.004% 
bromophenol blue, and 0.125 M Tris-HCl at a pH of 6.8. Scraping was done on ice, and the 
resulting lysates were boiled for 5 minutes. Proteins were then quantified on NanoDrop (ND-
1000 V 3.7.1) in order to achieve equal loading.  
Protein samples were separated by SDS-PAGE on 15% (for β-Actin, Bax, and Bcl-2) gels and 
transferred to PVDF membranes overnight at 30V. The membranes were then blocked with 
5% non-fat dry milk in PBS containing 0.1% Tween-20 for 1 hour at room temperature, with 
shaking. Membranes were then incubated with primary antibody at a concentration of 1:400 
for 2 hours at room temperature, with gentle shaking. After the incubation with the primary 
antibody, the membranes were washed for one hour with shaking. After washing, membranes 
were incubated with secondary antibody at a concentration of 1:1000 for 1 hour at room 
temperature. The membranes were then washed, and the bands visualized by treating the 
membranes with western blotting chemiluminescent reagent ECL (GE Healthcare). The 
results were obtained on an X-ray film (Agfa Healthcare).  
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2.9 Statistical analyses 
All experiments were carried out in triplicates in 3 independent experiments. Results were 
reported as the mean value ± standard deviation. Data were analyzed by one-way analysis of 
variance (ANOVA). The differences between the means of treated and control groups were 
tested for significance using Fisher’s least significant differences at P ≤ 0.05 (Fisher PLSD). An 
effect was considered significant when the value (±) of mean difference between groups 
exceeded Fisher PLSD in the one-factor ANOVA test. 
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Chapter III 
RESULTS 
 
3.1 Cytotoxicity of kefir  
The assessment of cytotoxicity by Trypan Blue exclusion method demonstrated that kefir’s 
IC50 for Caco-2 cells ranges between 11%, 10%, and 18% at 72, 48, and 24 hours respectively 
(Figures 8 A,B,C). For HT-29 cells, The IC50 was only reached at 48 and 72 hours of 
treatment (at the concentrations used), where it was determined to be 13% and 11% 
respectively (Figures 9 A, B, C). The arrows on the graphs indicate the IC50. At concentrations 
higher than the IC50, the viability of both cell lines decreased significantly 
(p≤0.05).Cytotoxicity levels were shown to be dose and time dependent, where maximum 
cytotoxicity (≈ 100%)of kefir on Caco-2 cells was achieved with 20% kefir (volume per 
volume) 48 hours post treatment (Figure 8C). Similarly, for HT-29 cells, the maximum 
cytotoxicity (≈ 100%) level was reached at 72 hours with 20% (Figure 9C). 
The cytotoxicity of the milk (the same type of milk which was used to produce the kefir) was 
also assessed.  The viability of both cell lines, 24, 48, and 72 hours after treatment with various 
milk concentrations, was not reduced, but rather, a slight increase in percentage viability was 
detected (Figures 8 A,B,C and 9 A,B,C).  
Results are reported as percent of viable cells out of the total number of cells (dead and alive). 
The differences between kefir and milk were significant, as determined by statistical analysis. It 
is important to note that this method doesn’t differentiate, among dead cells, between those 
that have undergone necrosis and those that have died through apoptosis. 
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Figure 8A: Viability of Caco-2 cells after 24 hours of treatment. Cells were treated with kefir  
and milk to establish different concentrations. Cell viability was then determined using the Trypan  
Blue Exclusion method. The arrows on the graph indicate the IC50. The results were expressed as  
percent of total number of cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
 
 
 
 Figure 8B: Viability of Caco-2 cells after 48 hours of treatment. Cells were treated with kefir  
and milk to establish different concentrations. Cell viability was then determined using the Trypan  
blue exclusion method. The arrows on the graph indicate the IC50.The results were expressed as  
percent of total number of cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
*  
* 
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 Figure 8C: Viability of Caco-2 cells after 72 hours of treatment. Cells were treated with kefir  
 and milk to establish different concentrations. Cell viability was then determined using the Trypan  
 Blue Exclusion method. The arrows on the graph indicate the IC50. The results were expressed as 
 percent of total number of cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
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 Figure 9A: Viability of HT-29 cells after 24 hours of treatment. Cells were treated with kefir 
 and milk to establish different concentrations. Cell viability was then determined using the Trypan 
 Blue Exclusion method. The results were expressed as percent of total number of cells. Data is 
 the mean -/+ SEM. 
  
 
 
 
 Figure 9B: Viability of HT-29 cells after 48 hours of treatment. Cells were treated with kefir 
 and milk to establish different concentrations. Cell viability was then determined using the Trypan 
 Blue Exclusion method. The arrows on the graph indicate the IC50. The results were expressed as  
 percent of total number of cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
* 
* 
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 Figure 9C: Viability of HT-29 cells after 72 hours of treatment. Cells were treated with kefir 
 and milk to establish different concentrations. Cell viability was then determined using the Trypan  
Blue Exclusion method. The arrows on the graph indicate the IC50. The results were expressed as 
 percent of total number of cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
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3.2 Kefir treatment reduces proliferation of Caco-2 and HT-29 cells. 
The same concentrations of milk and kefir, which were used for the cytotoxicity assay (0%, 
5%, 10%, 15%, 20% volume per volume) were applied on cells to assess their effect on 
proliferation. Results have shown that kefir significantly inhibited the proliferation of HT-29 
and Caco-2 cells (p≤0.05). The extent of this anti-proliferative effect was greater when the cells 
were treated with higher kefir concentrations and for longer periods of treatment (Figure 10 A, 
B, C and figure11 A, B, C). As compared to untreated Caco-2 cells, the percent decrease in 
proliferation reached a maximum of 97%, 125%, and 132%, at 24, 48, and 72 hours after 
treatment with the highest dose of kefir, respectively. At the kefir concentrations where the 
IC50 was calculated in the Trypan Blue Exclusion Method, the percent decrease was 95% at 24 
hours, 94% at 48 hours, and 97% at 72 hours (Figures 10 A, B, C). 
HT-29 cells as well showed significant inhibition of proliferation upon kefir treatment, even 
though the effect was slightly less than that exhibited by the Caco-2 cells. The maximum 
percent decrease achieved with 20% kefir treatment was 79%, 89%, and 96% at 24, 48, and 72 
hours after treatment, respectively (Figures 11 A, B, C). At the concentrations corresponding 
to the IC50, the percent decrease was calculated to be 60% at 48 hours, and 38% at 72 hours. 
As controls, cells were also treated with milk, at the same concentrations as kefir. All cells 
treated with milk showed a significant increase in proliferation, compared to the untreated 
cells. In both cell lines, the percent proliferation reached as high as 500%. The change in 
proliferation, designated by the activity of mitochondrial dehydrogenases, although significant, 
was not consistent. The response was not always dose- and time-dependent. However, in none 
of the milk-treated cells was the percent proliferation lower than that of the untreated cells. 
The differences between kefir and milk treatment were significant, as determined by statistical 
analysis. 
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Figure 10A: Proliferation of Caco-2 cells after 24 hours of treatment with different concentrations  
of milk and kefir. Cells were treated with kefir and milk to establish different concentrations Absorbance  
was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results 
 were normalized to the untreated cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
 
 
 
 
 
 
 
 Figure 10B: Proliferation of Caco-2 cells after 48 hours of treatment with different concentrations 
 of milk and kefir.  Cells were treated with kefir and milk to establish different concentrations Absorbance 
 was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results  
were normalized to the untreated cells. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
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Figure 10C: Proliferation of Caco-2 cells after 72 hours of treatment with different concentrations  
of milk and kefir. Cells were treated with kefir and milk to establish different concentrations Absorbance 
 was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results  
were normalized to the untreated cells. The stars above the bars indicate a percent proliferation higher  
than 200%. Data is the mean -/+ SEM.  The asterix signifies p<0.05. 
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Figure 11A: Proliferation of HT-29 cells after 24 hours of treatment with different concentrations  
of milk and kefir. Cells were treated with kefir and milk to establish different concentrations Absorbance 
 was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results  
were normalized to the untreated cells. The stars above the bars indicate a percent proliferation higher  
than 200%. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
 
 
 
 
 
 
 
Figure 11B: Proliferation of HT-29 cells after 48 hours of treatment with different concentrations  
of milk and kefir. Cells were treated with kefir and milk to establish different concentrations Absorbance 
 was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results  
were normalized to the untreated cells. The stars above the bars indicate a percent proliferation higher  
than 200%. Data is the mean -/+ SEM. The asterix signifies p<0.05. 
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Figure 11C: Proliferation of HT-29 cells after 72 hours of treatment with different concentrations  
of milk and kefir. Cells were treated with kefir and milk to establish different concentrations Absorbance 
 was measured at 450 nm after two hours of incubation with WST-1 cell proliferation reagent. Results  
were normalized to the untreated cells. The stars above the bars indicate a percent proliferation higher  
than 200%. Data is the mean -/+ SEM.  The asterix signifies p<0.05. 
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3.3 Kefir induces cell cycle arrest at the G1 phase. 
 After verifying that kefir was inhibiting cell proliferation in colorectal cancer cells, we aimed to 
evaluate whether this effect was through cell cycle arrest. Caco-2 and HT-29 cells were treated 
with 10% kefir and nonfermented milk for 24 hours and stained then with PI. Cell cycle 
analysis was done through flow cytometry. Through the analysis of their DNA content, cells 
were assigned to their respective phases: sub-G0/G1 cells were less than 2n, G0/G1 cells were 
2n, S/M phase cells were >2n. Treating the cells with kefir induced a shift in the cell cycle 
distribution, where the sub-G0/G1 DNA content was significantly higher in kefir-treated cells, 
compared to the nontreated controls. Correspondingly, the population of cells in S/M phase 
was reduced.  
In Caco-2 cells, the sub-G0/G1 population increased from 14 to 45.2 % as a result of 10% 
kefir treatment, while the S/M phase cells decreased from 15.5 to 3.6% (Figure 12A & C). On 
the other hand, when these cells were treated with 10% milk, a slight increase in sub-G0/G1 
population from 14 to 16.5% and a noticeable increase in S/M from 15.5 to 22.4% were 
detected (Figure 12A & B). 
The same pattern of cell cycle shift was seen upon treatment of HT-29 cells with 10% kefir. 
The sub-G0/G1 population increased from 13.9 to 52.7%, accompanied by a significant 
decrease in S/M phase population from 24.8 to 1.5% (Figure 12D&F). In contrast, the milk-
treated HT-29 cells showed a slight decrease in sub-G0/G1 cells from 13.9 to 12.6% and an 
obvious raise from 24.8 to 43.1% in the S/M phase population (Figure 12 D&F). The 
differences between kefir and milk treatment were significant, as determined by statistical 
analysis. 
It is thus implied that kefir causes a cell cycle arrest at the G1 transition checkpoint. These 
results explain the anti-proliferative effect of kefir that was detected through the WST-1 
proliferation assay.  
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Figure 12: Cell cycle analysis by flow cytometry. Caco-2 (upper panels) and HT-29 (lower panels)    cells 
were treated for 24 hours with 10% milk and kefir. Control cells were left untreated. After fixation overnight, 
cells were incubated with Propidium Iodide. Cells were analyzed using a C6 flow cytometer, which indicated 
the distribution of the cells into their respective cell cycle phases based on their DNA content.  Sub-G0/G1 
cells were less than 2n, G0/G1 cells were 2n, S/M phase cells were >2n. 
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3.4 Kefir has a proapoptotic effect on Caco-2 and HT-29 cells 
Kefir was shown to induce death through apoptosis in both colorectal adenocarcinoma cell 
lines. The results obtained from Cell Death Detection ELISAPLUS confirmed that the decreased 
viability upon kefir treatment, detected using Trypan Blue Exclusion method, involves the 
induction of apoptosis. DNA fragmentation is the hallmark of apoptosis. When the cell lysates 
are incubated in the presence of anti-histone-biotin and anti-DNA-peroxidase, the broken 
nucleosomes will be caught by the antibodies, while also getting bound streptavidin-coated 
microplate. In Cell Death Detection ELISA, the absorbance of ABTS at 405 nm, reflects the 
quantity of Anti-DNA peroxidase, which in turn reflects that of the nuleosomes generated by 
apoptosis. The enrichment factor, ratio of the absorbance measured for each concentration to 
that of the untreated controls, was calculated. Both colorectal adenocarcinoma cell lines 
showed an increase in the enrichment factors calculated upon kefir treatment. The increase 
was dose-dependent. In Caco-2 kefir-treated cells, the enrichment factor increased around 2.3, 
2.6, and 6 fold, 24 hours after treatment with 5%, 10%, and 15% kefir respectively (Figure 
13A). Upon 48 hours of treatment, the calculated enrichment factors showed a 3.5, 4, and 5.6 
fold increase with 5%, 10%, and 15% kefir respectively (Figure 13B). HT-29 cells also showed 
a significant increase in apoptosis induction upon kefir treatment, evident from the increase in 
the calculated enrichment factor.  In the 24-hour kefir-treated HT-29 cells, the enrichment 
factors were approximately 1.9, 2.4, and 6.3 upon treatment with 5%, 10%, and 15% kefir 
respectively (Figure 14A). Similarly, after 48 hours of kefir treatment, the fold increase in 
enrichment factor was significant in this cell line as well.  Treatment with 5%, 10%, and 15% 
kefir, yielded the following enrichment factors 1.3, 2.2, and 5.5 respectively (Figure 14B).  As in 
the cytotoxicity and proliferation assays, cells were also treated with the different milk 
concentrations, same as those of kefir, to assess the effect on apoptosis levels. In both cell 
lines, milk treatment induced a decrease in the apoptotic levels as compared to the untreated 
controls. The enrichment factors calculated for various milk concentrations were all less than 
1. The lowest value of enrichment factor was 0.5 for HT-29 cells, and 0.7 for Caco-2 cells 
obtained with 10%, 15% milk at 24 hours and 15% milk at 48 hours respectively (Figures 13 
A,B and 14 A,B).  The differences between kefir and milk treatment were significant, as 
determined by statistical analysis. 
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Figure 13A: Induction of apoptosis in Caco-2 cells 24 hr after kefir treatment. Cells were treated with 
noncytotoxic kefir concentrations and the corresponding milk concentrations. Absorbance was read at 405 nm 
after the addition of ABTS substrate. Results are shown as the enrichment factor (absorbance of sample dicvided 
by the absorbance of untreated control).  The asterix signifies p<0.05.   
 
 
 
 
 
Figure 13B: Induction of apoptosis in Caco-2 cells 48 hr after kefir treatment. Cells were treated with 
noncytotoxic kefir concentrations and the corresponding milk concentrations. Absorbance was read at 405 nm 
after the addition of ABTS substrate. Results are shown as the enrichment factor (absorbance of sample divided 
by the absorbance of untreated control).   The asterix signifies p<0.05. 
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Figure 14A: Induction of apoptosis in HT-29 cells 24 hr after kefir treatment. Cells were treated with 
noncytotoxic kefir concentrations and the corresponding milk concentrations. Absorbance was read at 405 nm 
after the addition of ABTS substrate. Results are shown as the enrichment factor (absorbance of sample divided 
by the absorbance of untreated control).   The asterix signifies p<0.05. 
 
 
 
 
 
Figure 14B: Induction of apoptosis in Caco-2 cells 48 hr after kefir treatment. Cells were treated with 
noncytotoxic kefir concentrations and the corresponding milk concentrations. Absorbance was read at 405 nm 
after the addition of ABTS substrate. Results are shown as the enrichment factor (absorbance of sample divided 
by the absorbance of untreated control).   The asterix signifies p<0.05. 
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3.5 Kefir induces apoptosis in a Bax/Bcl-2 dependent manner. 
To elucidate the mechanism through which kefir was causing the apoptotic death of the 
treated cells, Western Blot analysis was performed for Bax and Bcl-2. The results show that 
kefir promotes the expression of Bax. With respect to the nontreated controls (Figure 15 
upper panel lane 1), and the milk treated samples (Figure 15 upper panel lanes 2 and 3), the 
kefir treated samples (Figure 15 upper panel lanes 4 and 5) showed a significantly higher level 
of Bax. On the other hand, Bcl-2, the anti-apoptotic partner, was downregulated by kefir. As 
shown, the level of Bcl-2 detected in the kefir samples (Figure 15 middle panel lane 4 and 5) is 
much lower than in the non-treated control (Figure 15 middle panel lane 1) and the milk-
treated samples (Figure 15 middle panel lanes 2 and 3). β-Actin was used as an internal control 
to verify equal loading among the different samples (Figure 15 lower panel).  
 
Figure 15: Western Blot analysis for Bax and Bcl-2. Caco-2 cells were treated with 5% and 10% milk 
and kefir for 48 hours. Control cells were left untreated. At the end of the treatment period, cells were 
lysed and blotted for Bax (upper panel), Bcl-2 (middle panel), and β-Actin (lower panel) as internal 
loading control. 
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Chapter IV 
DISCUSSION 
 
Since its early origins, kefir has been shown to be beneficial to human health in many aspects 
(Adriana & Socaciu, 2008; Angulo, et al., 1993; Farnworth, 2005). It has been proven that kefir 
has potential as an antimicrobial, immunostimulatory, antimutagenic, and antinflammatory 
agent (Matsuu, et al., 2003; Nagira, et al., 2002; Rodrigues, et al., 2005; Silva, et al., 2009; 
Thoreux & Schmucker, 2001; G. Vinderola, Perdigon, Duarte, Farnworth, et al., 2006). Most 
importantly, many studies have highlighted an anti-cancerous role of kefir. The mechanisms 
behind this role are complex and still not fully known. Several in vivo studies on Sarcoma 180, 
Ehrlich carcinoma, Lewis Lung Carcinoma, and B16 melanoma, all showed that the 
administration of kefir retarded tumor growth in murine or rat cancer models (C. Chen, et al., 
2007; de Moreno de Leblanc, et al., 2007; Furuwaka, et al., 2000; Kubo, et al., 1992; Liu, et al., 
2005; Maalouf, et al., 2011; Murofushi, et al., 1983; Rizk, et al., 2009; Shiomi, et al., 1982). In 
the present study, we aimed to investigate whether kefir’s anti-cancerous effect, previously 
proven on several types of cancers, both in vivo and in vitro, also applies to colorectal cancer 
cell lines, in-vitro. The results obtained from this study are in accordance with previous in-vitro 
studies, on breast and leukemic cancer cell lines, which showed that kefir treatment possesses 
an antiproliferative and proapoptotic effect on these cancer cell lines (Chen, et al., 2007; 
Maalouf, et al., 2011; Rizk, et al., 2009).  
We first determined, through treating cells with increasing kefir concentrations, that the IC-50 
of kefir was reached with 18%, 10%, and 11% v/v at 24, 48, and 72 hours respectively, for 
Caco-2 cells, and 12% and 10% v/v at 48 and 72 hours respectively, for HT-29 cells. 
Treatment with higher concentrations was cytotoxic to the cells. The two cell lines showed a 
similar pattern in the viability decrease in response to kefir treatment. However, with HT-29 
cells, the IC-50 was not attained 24 hours after treatment, even with the highest dose used 
(20% v/v). The Trypan Blue Exclusion method does not differentiate, among dead cells, 
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between those that have died from apoptosis and those from necrosis. However, since 6 hours 
post-treatment, the viability of both cell types was not reduced, it was assumed that the cells 
were dying through apoptosis.  The fact that the milk treated cells showed no decrease in 
viability, suggests that kefir’s effect is due to products produced by the microorganisms during 
fermentation.  
Chen et al (2007), Maalouf et al (2011), and Rizk et al (2009) documented an inhibition of 
proliferation upon in vitro treatment of kefir. We aimed to see, if kefir has this same effect on 
colorectal cancer cell lines as well. As with breast and leukemic cancer cell lines, a notable 
decrease in proliferation was detected in the cells using the WST-1 reagent. The figures show 
that the decrease in proliferation is consistent with the decrease in viability. Caco-2 cells 
exhibited a 91%, 74%, and 96% decrease in proliferative activity upon treatment with 18%, 
12%, and 10% v/v at 24, 48, and 72 hours respectively (concentrations representing the IC-
50). For HT-29 cells, treatment with the concentrations at which the IC-50 was attained (12% 
and 10% v/v at 48 and 72 hours respectively), caused 64% and 40% decrease. In addition, as 
with all other assays, cells were treated with various milk concentrations. WST-1 assay results 
show an increase in proliferation. Milk is a rich source of many amino acids, vitamins, and 
minerals, which explains its ability to enhance proliferation. Similar results were obtained by 
Chen et al (2007), where a reduction in proliferation was seen upon treatment of MCF-7 
mammary cells with kefir, but proliferation increased upon their treatment with milk. Rizk et al 
(2009), and Maalouf et al (2011), as well, detected a significant reduction in proliferation levels, 
accompanied by an induction of apoptosis upon treatment of HTLV-1-negative malignant T-
lymphocytes with kefir (Maalouf, et al., 2011; Rizk, et al., 2009).  
We then aimed to examine if this antiproliferative effect was through interference in the cell 
cycle progression. Through flow cytometry, it was verified that kefir causes a shift in the cell 
cycle of the treated cells towards the sub-G0/G1 phase, by inducing cell cycle arrest at the G1 
checkpoint. Kefir did not only increase the percentage of cells in the sub-G0/G1 phase, but 
caused a reduction in the S/M cell population as well. The G1 arrest implies that kefir induces 
death in colorectal cancer cell lines.  
To verify that the cells were dying though the mechanism of apoptosis, as assumed, the Cell 
Death Elisa Kit assay was performed. The results of this assay confirmed that kefir was indeed 
inducing apoptosis in Caco-2 and HT-29 cells. When these cells were treated with higher kefir 
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concentrations, the level of apoptosis induction showed a significant increase. Hence, the 
reduction in viability, which was seen in the Trypan Blue Exclusion Method, was achieved 
through apoptosis, rather than necrosis.  Unfermented milk, when applied to Caco-2 and HT-
29 cells, didn’t show any induction of apoptosis. This explains the lack of any reduced cell 
viability seen in the Trypan Blue Exclusion Method in the milk-treated cells. In addition, the 
results of the milk treatment again suggest a possible role for the fermentation products in the 
proapoptotic role.   
Bcl-2 acts as a repressor of the apoptotic pathway, while Bax, counters this action, and 
promotes apoptosis. The ratio of Bax and Bcl-2 in a cell reflects the activation of the survival 
or apoptotic pathways (Oltvai, Milliman, & Korsmeyer, 1993). Because kefir was clearly 
inducing apoptosis in both colorectal cancer cell lines, we aimed to find out if the apoptotic 
pathway that was activated by kefir involved Bax and Bcl-2. Western Blot analysis was used, 
and the results showed that treating the cells with noncytotoxic kefir concentrations had 
triggered the expression of Bax, the proapoptotic protein, while simultaneously inducing a 
downregulation of Bcl-2, the anti-apoptotic protein. The milk-treated cells, on the other hand, 
showed the opposite response, an upregulation of Bcl-2 and a downregulation of Bax. These 
results suggest that kefir, which was shown to cause the death of the cancer cells (through the 
Trypan Blue Ecxlusion Method and the Cell Death Elisa Kit), was doing so through the 
activation of the Bax/Bcl-2 apoptotic pathway. The apoptotic pathway, which involves the 
couple Bax and Bcl-2 begins with the activation of AMPK. The latter is known to control 
apoptosis in several cancers, including colorectal cancer (Oda, et al., 2000). Downstream of 
AMPK is p53, whose up-regulation in turn causes the up-regulation of the pro-apoptotic Bax 
and the anti-apoptotic Bcl-2 (Oda, et al., 2000; Prives & Hall, 1999). The disturbance in the 
normal balance between Bax and Bcl-2, in favor of Bax, triggers the activation of Caspase-3. 
This in turn causes the proteolytic cleavage of PARP, thus triggering apoptosis (Green & 
Amarante-Mendes, 1998). Since kefir was found to modulate the expression of Bax and Bcl-2, 
it would be interesting to verify if its effect on these two proteins is direct or indirect, possibly 
through effectors in this pathway (Figure 16). 
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Figure 16: Possible pathway for kefir’s proapoptotic effect 
 
Rizk et al (2009) and Maalouf et al (2011) who showed an antiproliferative effect of kefir in 
HTLV-1-negative malignant T-lymphocytes, used RT-PCR to study the transcriptional level of 
TGF-α, TGF-β1, and MMP-2. Their results showed that kefir inhibited TGF-α and 
upregulated TGF-β1, thus explaining the decreased proliferation of the kefir-treated 
lymphocytes. Further investigation, should examine if kefir has similar mechanisms in 
colorectal cancer cell lines. Our results, along with those just mentioned, suggest that kefir may 
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have a pleiotropic effect, altering the expression of different proteins and genes, involved in 
various pathways, all leading to an antiproliferative and proapoptotic effect in cancer cells. 
The active component behind kefir’s anti-cancerous and other beneficial effects is still 
unidentified. The potential constituents include bacterial cell wall components, microbial 
DNA, peptides, and exopolysaccharides (Hong, et al., 2010; Thoreux & Schmucker, 2001; G. 
Vinderola, Perdigon, Duarte, Farnworth, et al., 2006). Chen et al (2007) who demonstrated the 
antiproliferative role of kefir on mammary cancer cells, detected a change in peptide content 
during kefir fermentation, to which the anti-cancer effects could be attributed (Chen, et al., 
2007). Future work should aim to identify and isolate kefir’s active ingredient.  
In the present study, we were unable to determine the cytotoxicity of kefir in normal colorectal 
cells, due to the unavailability of such cell lines. However, kefir is a highly consumable product, 
without any known negative side effects on the gastrointestinal tract. Rather, kefir has been 
shown to be beneficial the digestive system, and hence it was assumed to be non-cytotoxic to 
normal colorectal cells. Further studies, should however, assert this assumption, through 
determining effect of the different kefir concentrations, on normal colon cell lines.  
There have been several studies, similar to the current one, which aim to identify and test 
potential antiproliferative and proapoptotic agents on colorectal cancer cell lines in vitro. Such 
agents and compounds include osteopontin, fungal extracts, berry extracts, curcumin, and 
quercetin (Kim, et al., 2010; Lavi, Friesem, Geresh, Hadar, & Schwartz, 2006; Lavi, et al., 2010; 
Likui, Hong, Shuwen, Yuangang, & Yan, 2011; McDougall, Ross, Ikeji, & Stewart, 2008; 
Shehzad, Wahid, & Lee, 2010). Most of these studies were done on Caco-2 and/or HT-29 
cells, and they all aimed to find if the compound or extract of interest could, someday, become 
a therapeutic target for CRC. One such compound, curcumin (diferuloylmethane), has entered 
several clinical trials, and has completed phase I in some trials for its potential employment in 
CRC treatment. One study showed that curumin’s IC50 on HT-29 cells was 50 µM (Singh, 
Shrivastav, & Sharma, 2009). Various studies showed that curcumin was responsible for the 
overexpression of Bax and p53, and the underexpression of Bcl-2 (Shehzad, et al., 2010; Su, et 
al., 2006). Kefir’s anti-cancerous potential, demonstrated by this and many other studies, is 
comparable to that of curcumin, which suggests that clinical trials for kefir may be feasible. 
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In all the experiments that were done in this study, both cell lines, Caco-2 and HT-29 cells, 
showed a similar pattern in their responses to kefir and milk treatment. Although there were 
differences in the extent of the response in some cases, both cell lines exhibited the same 
results. This implies that kefir’s mechanism is not cell-line specific, but rather, applies to 
colorectal cancer cells in general. 
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Chapter V 
CONCLUSION 
 
Kefir has become globally known as a complex probiotic, to which many health benefits have 
been attributed. These include anti-microbial, anti-inflammatory, immunomodulatory, and 
metabolic benefits. In this study, our main concern was kefir’s anti-cancerous potential. Through 
several experiments, we have established that kefir exhibits proapoptotic and antriproliferatove 
properties on colorectal adenocarcinoma cells, namely Caco-2 and HT-29, in vitro. It was also 
demonstrated that kefir causes cell cycle arrest at the G1 phase. Westren Blot analysis 
demonstrated that kefir induces the overexpression of Bax, while repressing Bcl-2, thus depicting 
a possible pathway through which kefir intervenes to cause apoptosis of the malignant cells. The 
results of all experiments, which were correspondingly done milk treatment, affirm that kefir’s 
beneficial effects are due to products produced by the microorganisms during fermentation. 
Further work should attempt to determine the exact pathway on which kefir works to cause 
apoptosis, cell cycle arrest, and reduced proliferation. Expression levels should be studied at the 
level of RNA and proteins. On the other hand, the active component of kefir should be 
identified. 
The results obtained by this study are promising, and can pave way to in-vivo studies, and later 
on clinical trials.  
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